Mental Status Changes Postchemoembolization: The Role of Inflammatory Response

Daniel Wells; Joseph Alisky; Charles E. Ray Jr.

doi:10.1055/s-0033-1342965

Seminars in Interventional Radiology, Table of Contents

Semin intervent Radiol 2013; 30(02): 219-222
DOI: 10.1055/s-0033-1342965

Morbidity and Mortality

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Mental Status Changes Postchemoembolization: The Role of Inflammatory Response

Authors

Daniel Wells

¹Departments of Radiology
Joseph Alisky

²Departments of Hospitalist Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado
Charles E. Ray Jr.

¹Departments of Radiology

Abstract

Full Text

References

References
1 Marcantonio ER, Goldman L, Mangione CM , et al. A clinical prediction rule for delirium after elective noncardiac surgery. JAMA 1994; 271 (2) 134-139
2 de Rooij SE, van Munster BC, Korevaar JC, Levi M. Cytokines and acute phase response in delirium. J Psychosom Res 2007; 62 (5) 521-525
3 Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12 (3) 321-326
4 Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol 2000; 11 (4) 453-460
5 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
6 Matsuda Y, Kawata S, Nagase T , et al. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. Cancer 1994; 73 (1) 53-57
7 Blanco Vela CI, Bosques Padilla FJ. Determination of ammonia concentrations in cirrhosis patients—still confusing after all these years?. Ann Hepatol 2011; 10 (Suppl. 02) S60-S65
8 Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization syndrome. Semin Intervent Radiol 2011; 28 (2) 207-211
9 Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol 2000; 11 (4) 453-460
10 Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332 (19) 1256-1261
11 Lopez Jr RR, Pan SH, Lois JF , et al. Transarterial chemoembolization is a safe treatment for unresectable hepatic malignancies. Am Surg 1997; 63 (10) 923-926
12 Brown KT, Nevins AB, Getrajdman GI , et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 1998; 9 (5) 822-828
13 Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol 2000; 11 (4) 453-460
14 Paye F, Farges O, Dahmane M, Vilgrain V, Flejou JF, Belghiti J. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg 1999; 86 (2) 176-180
15 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
16 Lewandowski RJ, Mulcahy MF, Kulik LM , et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010; 255 (3) 955-965
17 Lance C, McLennan G, Obuchowski N , et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22 (12) 1697-1705
18 Castells A, Bruix J, Ayuso C , et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995; 22 (4) 410-415
19 Paye F, Farges O, Dahmane M, Vilgrain V, Flejou JF, Belghiti J. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg 1999; 86 (2) 176-180
20 Wigmore SJ, Redhead DN, Thomson BN , et al. Postchemoembolisation syndrome—tumour necrosis or hepatocyte injury?. Br J Cancer 2003; 89 (8) 1423-1427
21 Matsuda Y, Kawata S, Nagase T , et al. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. Cancer 1994; 73 (1) 53-57
22 Itoh Y, Okanoue T, Ohnishi N , et al. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. Liver 1999; 19 (2) 97-103
23 Ikei S, Ogawa M, Beppu T , et al. Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepato-cellular carcinoma. Cytokine 1992; 4 (6) 551-564
24 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol 2012; 33 (1) 33-40
25 Pirisi M, Fabris C, Soardo G , et al. Hepatic release of erythropoietin induced by transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 1995; 22 (1) 148-152
26 Ramlawi B, Rudolph JL, Mieno S , et al. C-Reactive protein and inflammatory response associated to neurocognitive decline following cardiac surgery. Surgery 2006; 140 (2) 221-226
27 Adamis D, Lunn M, Martin FC , et al. Cytokines and IGF-I in delirious and non-delirious acutely ill older medical inpatients. Age Ageing 2009; 38 (3) 326-332 , discussion 251